Company news: ViroPharma and DIME

Share this article:

Specialty drug company ViroPharma teamed with several medical societies on the launch of a program designed to unite specialists treating patients with the orphan condition hereditary angioedema (HAE). The main component of the program—called HAE: Learn About It, Talk About It—is the website LetsTalkHAE.com, which offers tools designed to readily diagnose and properly manage patients with the rare, potentially fatal swelling disorder. A joint effort initially targeting allergists and gastroenterologists, the program has grown to include NPs, PAs and emergency physicians. ViroPharma markets HAE therapy Cinryze.

Accredited med ed provider DIME launched a web browser designed to facilitate internet searching-and-learning, in which clinicians hunt online for answers to clinical questions in exchange for credit. The tool, called iPointOfCare, integrates across all browsers and devices and is optimized for the mobile environment, DIME said. About 116,000 physicians participated in this form of education in 2009, according to the ACCME.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.